Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 (The CoDEX Randomized Clinical Trial)

Primary objective: To evaluate the effectiveness of early intravenous (IV)  dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe ARDS due to confirmed or probable COVID-19. 


Type of studyInterventionalRCT, Phase 3  


Treatment testedHydroxycortisone 


Countries: Brazil


Number of sites53


Sample size350


Study participants:  Adults, Probable or confirmed infection by SARS-COV-2, Intubated and Mechanically ventilated, Moderate/Severe ARDS with onset <48h.


Study statusCompleted


Study documents


Principal investigator

  • Luciano Cesar Pontes Azevedo, Ph.DTeaching Director of Teaching & Research Institute Sírio-Libanês Hospital 


More information




Last updated: September 2020


Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.